279 related articles for article (PubMed ID: 19553086)
1. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B
Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R
Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328
[TBL] [Abstract][Full Text] [Related]
5. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.
McCue RE; Waheed R; Urcuyo L; Orendain G; Joseph MD; Charles R; Hasan SM
Br J Psychiatry; 2006 Nov; 189():433-40. PubMed ID: 17077434
[TBL] [Abstract][Full Text] [Related]
7. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
[TBL] [Abstract][Full Text] [Related]
10. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Hatta K; Takebayashi H; Sudo Y; Katayama S; Kasuya M; Shirai Y; Morikawa F; Nakase R; Nakamura M; Ito S; Kuga H; Nakamura M; Ohnuma T; Usui C; Nakamura H; Hirata T; Sawa Y;
Psychiatry Res; 2013 Dec; 210(2):396-401. PubMed ID: 23919898
[TBL] [Abstract][Full Text] [Related]
11. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
13. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
Hatta K; Otachi T; Sudo Y; Hayakawa T; Ashizawa Y; Takebayashi H; Hayashi N; Hamakawa H; Ito S; Nakase R; Usui C; Nakamura H; Hirata T; Sawa Y;
Schizophr Res; 2011 May; 128(1-3):127-35. PubMed ID: 21420283
[TBL] [Abstract][Full Text] [Related]
14. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
15. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
Al-Dhaher Z; Kapoor S; Saito E; Krakower S; David L; Ake T; Kane JM; Correll CU; Carbon M
J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):458-70. PubMed ID: 27093218
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS;
Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
[TBL] [Abstract][Full Text] [Related]
19. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Soares-Weiser K; Béchard-Evans L; Lawson AH; Davis J; Ascher-Svanum H
Eur Neuropsychopharmacol; 2013 Feb; 23(2):118-25. PubMed ID: 22633617
[TBL] [Abstract][Full Text] [Related]
20. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
